Medicine·YesterdayShort-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney diseaseCohort study of 126 peopleChronic kidney diseasePaper
Diabetes, Obesity & Metabolism·9 SepA Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal TolerabilityExperiments in animalsInterventionsPaper